.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Cipla
Queensland Health
Fish and Richardson
Medtronic
Fuji
Dow
AstraZeneca
Moodys

Generated: June 26, 2017

DrugPatentWatch Database Preview

Pazopanib hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for pazopanib hydrochloride and what is the scope of pazopanib hydrochloride patent protection?

Pazopanib hydrochloride
is the generic ingredient in one branded drug marketed by Novartis Pharms Corp and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pazopanib hydrochloride has thirty-four patent family members in twenty-five countries.

There are three drug master file entries for pazopanib hydrochloride. Two suppliers are listed for this compound.

Summary for Generic Name: pazopanib hydrochloride

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: see list3
Suppliers / Packagers: see list2
Bulk Api Vendors: see list45
Clinical Trials: see list2,452
Patent Applications: see list88
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:pazopanib hydrochloride at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
VOTRIENT
pazopanib hydrochloride
TABLET;ORAL022465-001Oct 19, 2009RXYesYes7,105,530► SubscribeYY ► Subscribe
Novartis Pharms Corp
VOTRIENT
pazopanib hydrochloride
TABLET;ORAL022465-001Oct 19, 2009RXYesYes8,114,885► SubscribeYY ► Subscribe
Novartis Pharms Corp
VOTRIENT
pazopanib hydrochloride
TABLET;ORAL022465-002Oct 19, 2009DISCNNoNo8,114,885► SubscribeYY ► Subscribe
Novartis Pharms Corp
VOTRIENT
pazopanib hydrochloride
TABLET;ORAL022465-002Oct 19, 2009DISCNNoNo► Subscribe► Subscribe
Novartis Pharms Corp
VOTRIENT
pazopanib hydrochloride
TABLET;ORAL022465-002Oct 19, 2009DISCNNoNo7,262,203► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: pazopanib hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,858,626Pyrimidineamines as angiogenesis modulators► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: pazopanib hydrochloride

Country Document Number Estimated Expiration
New Zealand526542► Subscribe
Norway2010020► Subscribe
Portugal2311825► Subscribe
HungaryS1700003► Subscribe
Japan4253188► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PAZOPANIB HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
710Luxembourg► Subscribe91710, EXPIRES: 20250614
00456Netherlands► SubscribePRODUCT NAME: PAZOPANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER PAZOPANIB HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614
C/GB10/032United Kingdom► SubscribePRODUCT NAME: PAZOPANIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU 1/10/628/001 20100614; UK EU 1/10/628/002 20100614; UK EU 1/10/628/003 20100614; UK EU 1/10/628/004 20100614
/2010Austria► SubscribePRODUCT NAME: PAZOPANIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/628/001 - EU/1/10/628/004 20100614
9Finland► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Chubb
Federal Trade Commission
Cipla
Mallinckrodt
US Army
Queensland Health
Baxter
Cerilliant
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot